Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...
Key market opportunities in the blood glucose monitoring sector arise from technological advancements like cloud-connected devices and digital health apps, increasing remote monitoring. Rising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback